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PRelation of Beta-Blocker–Induced Heart Rate
Lowering and Cardioprotection in Hypertension
Sripal Bangalore, MD, MHA, Sabrina Sawhney, MD, Franz H. Messerli, MD
New York, New York
Objectives The purpose of this study was to evaluate the role of heart rate reduction with beta-blockers on the risk of car-
diovascular events in patients with hypertension.
Background Resting heart rate has been shown to be a risk factor for cardiovascular morbidity and mortality in the general
population and in patients with heart disease such as hypertension, myocardial infarction, and heart failure. Con-
versely, pharmacological reduction of heart rate is beneficial for patients with heart disease. However, the role of
pharmacological reduction of heart rate using beta-blockers in preventing cardiovascular events in patients with
hypertension is not known.
Methods We conducted a MEDLINE/EMBASE/CENTRAL database search of studies from 1966 to May 2008. We in-
cluded randomized controlled trials that evaluated beta-blockers as first-line therapy for hypertension with
follow-up for at least 1 year and with data on heart rate. We extracted the baseline characteristics, the
blood pressure response, heart rate at the baseline and end of trial, and cardiovascular outcomes from
each trial.
Results Of 22 randomized controlled trials evaluating beta-blockers for hypertension, 9 studies reported heart rate data.
The 9 studies evaluated 34,096 patients taking beta-blockers against 30,139 patients taking other antihyper-
tensive agents and 3,987 patients receiving placebo. Paradoxically, a lower heart rate (as attained in the beta-
blocker group at study end) was associated with a greater risk for the end points of all-cause mortality (r 0.51;
p  0.0001), cardiovascular mortality (r 0.61; p  0.0001), myocardial infarction (r 0.85; p  0.0001),
stroke (r  0.20; p  0.06), or heart failure (r  0.64; p  0.0001). The same was true when the heart rate dif-
ference between the 2 treatment modalities at the end of the study was compared with the relative risk reduction for
cardiovascular events.
Conclusions In contrast to patients with myocardial infarction and heart failure, beta-blocker–associated reduction in heart
rate increased the risk of cardiovascular events and death for hypertensive patients. (J Am Coll Cardiol 2008;
52:1482–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.048o
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aesting heart rate has been shown to be an independent risk
actor for cardiovascular morbidity and mortality for patients
ithout cardiovascular disease (1), for patients with acute
yocardial infarction (MI) (2) or hypertension (3,4), and for
atients with known coronary artery disease (CAD) (5,6).
Given that higher resting heart rate is a risk factor,
lowing it should have beneficial effects. In fact, exercise
s a well-known intervention serving to lower resting
eart rate and to increase survival. Kjekshus et al. (7), in
meta-analysis of randomized controlled trials (RCTs)
rom the Department of Medicine, Division of Cardiology, St. Luke’s Roosevelt
ospital and Columbia University College of Physicians and Surgeons, New York,
ew York. Dr. Messerli is a member of the Speakers’ Bureau for Abbott, Glaxo-
mithKline, Novartis, Pfizer, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-
yers Squibb, Forest, Sankyo, and Sanofi, and has received research funding/grants
rom GlaxoSmithKline, Pfizer, Novartis, and CardioVascular Therapeutics.n
Manuscript received March 7, 2008; revised manuscript received June 3, 2008,
ccepted June 6, 2008.f acute MI and post-MI trials, showed that reduction of
eart rate by beta-blockers is closely related to reduction
n infarct size (in acute MI trials) and to reduction in
ortality and nonfatal MI in long-term trials. Similar
eneficial effects of heart rate reduction have been ob-
erved in meta-analyses of RCTs of patients with heart
ailure (8) and angina pectoris. As a result of these
tudies, it has become a common clinical contention to
scribe the “cardioprotective” effect of beta-blockers to
heir heart lowering effect: the slower the heart rate, the
reater the benefit.
See page 1490
Whether the beneficial effects of heart rate reduction with
beta-blocker are applicable to patients with hypertension is
ot known.
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earch strategy. Eligible trials had to fulfill the following
riteria to be included in this analysis: 1) RCTs with
omparison of regimen based on beta-blockers with other
gents (including placebo) in patients with hypertension; 2)
eta-blocker usage as first-line therapy for hypertension; 3)
ollow-up of at least 1 year; and 4) evaluation of cardiovas-
ular outcomes data on heart rate.
ata sources and study search. We conducted a MED-
INE/EMBASE/CENTRAL search of studies using the
erms “beta adrenergic blockers,” “adrenergic beta antago-
ist,” “beta-blockers,” and “hypertension.” We limited our
earch to studies in human subjects and in the English
anguage in peer-reviewed journals from 1966 to May 2008.
e checked the reference lists of reviewed articles, prior
eta-analyses, and original studies identified by the elec-
ronic search to find other potentially eligible studies. Trials
hat were only in abstract form without a manuscript
ublished were not considered for this analysis.
tudy selection. Two authors (S.B. and S.S.) indepen-
ently assessed trial eligibility (  0.96). Disagreements
ere resolved by consensus.
nd points and data extraction. Outcomes of interest
ere all-cause mortality, cardiovascular mortality, MI,
troke, and heart failure considered separately. We extracted
he inclusion/exclusion criteria, publication year, sample
ize, age, first-line antihypertensive agents used, blood
ressure and heart rate before randomization and at the end
f the study, length of follow-up, and the above outcomes of
nterest for each of the studies.
tatistical analysis. Statistical analysis was done using
tandard software (Stata 9.0, Stata Corp., College Station,
exas) using the METAN program (9). The pooled effect
or each grouping of trials was derived from the point
stimate for each separate trial weighted by the inverse of
he variance (1/SE2). Heterogeneity was assessed using Q
chi-square) statistics and/or the I2 statistics (10). If trials
ere homogeneous (p  0.10), a fixed-effect model was
sed to calculate pooled effect sizes. Otherwise, a random-
ffects model of DerSimonian and Laird (11) was applied to
alculate overall differences. Publication bias was estimated
sing the weighted regression test of Egger.
eta-regression analysis. Meta-regression analyses were
erformed to evaluate the relationship between heart rate at
reatment end on beta-blocker therapy and the risk of
ardiovascular outcomes. A curve fit analysis was performed
o evaluate the best regression fit. The analysis was weighted
y the weight of each trial for the specific outcomes. The p
alue was considered significant at 0.05.
esults
e identified 22 RCTs in which beta-blockers were used as
rst-line agents, patients were followed up for at least 1
ear, and cardiovascular outcomes were evaluated. Of the
2 RCTs, 9 trials had data on heart rate and werencluded for this analysis (Fig.
). We excluded the results
rom the MAPHY (Metoprolol
therosclerosis in Hyperten-
ion) trial (12), as this was a
ubgroup from the HAPPHY
Heart Attack Primary Preven-
ion in Hypertension trial) (13).
haracteristics of the trials.
he baseline characteristics and
nclusion criteria are summarized
n Tables 1 (14–21) and 2. The 9 RCTs evaluated 68,220
atients with hypertension: 34,096 patients (50%) randomly
ssigned to the beta-blocker arm, 3,987 (6%) randomly
ssigned to placebo, and 30,137 (44%) randomly allocated
o other antihypertensive agents. Of the patients in the
eta-blocker arm, 26,527 (78%) received atenolol, 3,185
9%) received oxprenolol, 275 (1%) received propranolol,
nd 4,109 (12%) received atenolol/metoprolol/pindolol or
ydrochlorothiazide. In the comparison group, 3,987 pa-
ients (12%) were given placebo, 4,605 patients (13%)
eceived angiotensin-receptor blockers, 3,603 (11%) re-
eived diuretics, and 21,929 (64%) received calcium-channel
lockers.
eta-blocker versus comparison baseline characteristics. The
verage (weighted) mean age of the patients in the trials was
8 years, and patients were followed up for a mean of 3.5
ears (Table 3). The beta-blocker and the comparison
roups were similar with respect to the mean age, follow-up
uration, and baseline systolic and diastolic pressures
weighted). In the beta-blocker group, the average weighted
aseline systolic pressure decreased by 13.5% (166.2  14.6
Figure 1 Selection of Studies
BB  beta-blockers; HTN  hypertension; RCT  randomized controlled trial.
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
MI  myocardial infarction
RCT  randomized
controlled trial
RR  relative risk
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iastolic blood pressure by 14.2% (100.4  6.8 mm Hg to
6.1 6.7 mm Hg; p 0.0001) (Table 3). Similarly, in the
omparison group, the average weighted baseline systolic
ressure decreased by 13.1% (166.7  14.7 mm Hg to 144.9
17.3 mm Hg; p  0.0001) and the diastolic blood
ressure by 13.3% (100.4  7.3 mm Hg to 87  7.7 mm
g; p  0.0001) (Table 3). There was no difference
etween the final attained systolic and diastolic blood
ressure between the beta-blocker and the comparison
roups. However, beta-blockers caused a significant de-
rease (12%) in heart rate, whereas the comparison group
ad a nonsignificant decrease (1%) in heart rate. Thus, there
eneral Characteristics of Included Trials: Hemodynamics
Table 2 General Characteristics of Included Trials: Hemodynam
Trial (Ref. #)
Mean Age
(yrs)
Men
(%)
BB HR (beats/min)
Baseline/Final
Versus placebo
IPPPSH (14) 52 100 79.8/72
STOP (15) 76 37 77/NR
Versus other antihypertensive
agents
ASCOT (16) 63 77 71.8/61.3
ELSA (17) 56 55 76/66
HAPPHY (13) 52 100 77/64
INVEST (18) 66 48 75.5/69.2
LIFE (19) 67 46 73.7/66
VACS (20) 50 100 77/60.9
Yurenev et al. (21) 45 100 70.2/66
eneral Characteristics of Included Trials
Table 1 General Characteristics of Included Trials
Trial (Ref. #), Year Patient Characteristics Number o
Versus placebo
IPPPSH (14), 1985 Hypertension but no CAD 6,
STOP (15), 1991 Hypertension but no MI, angina, or
stroke in prior 12 months
1,
Versus other antihypertensive
agents
ASCOT (16), 2005 Hypertension and at least 1 other
cardiovascular risk factor but no
CAD
19,
ELSA (17), 2002 Hypertension; excluded patients with
no baseline or 1 follow-up
carotid ultrasound
2,
HAPPHY (13), 1987 Hypertension without MI, angina,
CVA
6,
INVEST (18), 2003 CAD and hypertension 22,
LIFE (19), 2002 Hypertension and LVH; no MI or CVA
in prior 6 months
9,
VACS (20), 1982 Men with hypertension (DBP 95–114
mm Hg)
Yurenev et al. (21), 1992 Men with hypertension (160/95
mm Hg) and different degree of
LVH and no CAD
SCOT Anglo-Scandinavian Cardiac Outcomes Trial; BFZ bendrofluazide; CAD coronary arter
tudy on Atherosclerosis; HAPPHY Heart Attack Primary Prevention in Hypertension trial; HCTZ
rospective Primary Prevention Study in Hypertension; LIFE  Losartan Intervention for End point
ld Patients With Hypertension; VACS  Veterans Administration Cooperative Study Group on AnB  beta-blocker; BP  blood pressure; HR  heart rate; NR  not reported; other abbreviations as inas a 12% lower heart rate in the beta-blocker group
ompared with the comparison agent at the end of the trial
p  0.0001) (Table 3).
ardiovascular mortality. For the outcome of cardiovas-
ular mortality (7 RCTs reporting this outcome), the risk
eduction was comparable between the beta-blocker group
nd the comparison group (3.3% vs. 3.0%; pooled relative
isk [RR]: 1.05; 95% confidence interval [CI]: 0.88 to 1.25;
 0.615). Given heterogeneity in the analysis (heteroge-
eity chi-square  18.11 [df  7]; p  0.011; I2  61.4%;
au2  0.0283), a random effects model was used. How-
ver, the tests for publication bias were negative (Begg’s test
 0.902; Egger’s p  0.650).
ntrols HR (beats/min)
Baseline/Final
Mean Baseline BP
(mm Hg)
Study End BP (BB–Controls)
(mm Hg)
80.1/77 173/108 3.8/1.2
76/NR 195/102 19.5/8.1
71.9/72.5 164/95 2.7/1.9
76.3/76.3 163/101 1.5/0.2
77/75 166/107 0.0/1.0
75.6/72.8 151/87 1
73.9/72.1 174/98 1.1/0.2
76.6/79.5 145/101 9.2/1.8
68.8/68.6 168/106 3.4/1.4
ents Follow-Up (yrs) Beta-Blocker Comparison
4.0 Oxprenolol Placebo
2.1 Atenolol/metoprolol/pindolol/
HCTZ/amiloride
Placebo
5.5 Atenolol Amlodipine
3.8 Atenolol Lacidipine
3.8 Atenolol or metoprolol Bendrofluazide/HCTZ
2.7 Atenolol Verapamil SR
4.8 Atenolol Losartan
1 Propranolol HCTZ
4 Propranolol Diuretic
se; CVA cerebrovascular accident; DBP diastolic blood pressure; ELSA European Lacidipine
lorothiazide; INVEST International Verapamil SR and Trandolapril study; IPPPSH International
ion trial; LVH  left ventricular hypertrophy; MI  myocardial infarction; STOP  Swedish Trial in
ensive Agents.ics
Cof Pati
357
627
257
334
569
576
222
394
304
y disea
hydrochTable 1.
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October 28, 2008:1482–9 Beta-Blockers and Heart RateThe relationship between heart rate at the end of treat-
ent and risk of cardiovascular mortality followed an
nverse linear relationship (y  3.5913  0.0375x; r 
0.6133; p  0.00001), so that the relative risk of cardio-
ascular mortality increased with decreasing heart rate at
reatment end (Fig. 2).
onfatal MI. For the outcome of nonfatal MI (8 RCTs
eporting this outcome), the risk reduction was comparable
etween the beta-blocker group and the comparison group
3.2% vs. 3.0%; pooled RR: 1.05; 95% CI: 0.96 to 1.14; p
.275). There was no heterogeneity in the analysis (heter-
geneity chi-square  5.34 [df  8]; p  0.721; I2  0.0%;
au2 0.0000). The tests for publication bias were negative
Begg’s test p  0.917; Egger’s p  0.490).
The relationship between heart rate at the end of treat-
ent and risk of nonfatal MI followed an inverse linear
ummary Statistics of the Included Trials
Table 3 Summary Statistics of the Included Trials
Variable
Beta-Blocker
(n  34,096)
Comparison
(n  34,124) p Value
Age, yrs 58 10 58 10 1.000
Follow-up, yrs 3.5 1.4 3.5 1.4 1.000
Systolic BP baseline, mm Hg 166.2 14.6 166.7 14.7 0.948
Diastolic BP baseline, mm Hg 100.4 6.8 100.4 7.3 0.986
Systolic BP final, mm Hg 143.8 10.6 144.9 17.3 0.874
Diastolic BP final, mm Hg 86.1 6.7 87 7.7 0.790
Heart rate baseline, beats/min 75 3 75 3 0.584
Heart rate final, beats/min 66 4 74 3 0.0001
P  blood pressure.
Figure 2 Risk of Cardiovascular
Mortality as Function of Heart Rate
Relative risk of cardiovascular mortality as a function of heart rate achieved at the
end of the study in the beta-blocker group. The diameter of the circles represents
the weight of each individual trial. The line represents the regression fit with 95%
confidence interval for the effect sizes. ASCOT  Anglo-Scandinavian Cardiac
Outcomes Trial; bpm  beats/min; CV  cardiovascular; ELSA  European
Lacidipine Study on Atherosclerosis; HAPPHY  Heart Attack Primary Preven-
tion in Hypertension; INVEST  International Verapamil SR and Trandolapril
study; IPPSH  International Prospective Primary Prevention Study in Hyperten-
sion; LIFE  Losartan Intervention for End point Reduction trial.elationship (y  0.8788  0.021x; r  0.6948; p 
.00001) so that the relative risk of nonfatal MI increased
ith decreasing heart rate at treatment end (Fig. 3). A
imilar inverse linear relationship was also seen when the
ifference in heart rate at treatment end was plotted against
he risk of nonfatal MI, suggesting that the more efficacious
eta-blockers were at reducing heart rate, the greater the
isk of nonfatal MI (Fig. 4).
Figure 4 Risk of Nonfatal MI as Function
of Heart Rate Difference Between Treatments
Relative risk of nonfatal MI as a function of heart rate difference between treat-
ment modalities. The diameter of the circles represents the weight of each
individual trial. The line represents the regression fit with 95% confidence inter-
val for the effect sizes. STOP  Swedish Trial in Old Patients With Hyperten-
sion; other abbreviations as in Figure 2.
Figure 3 Risk of Nonfatal MI as Function of Heart Rate
Relative risk of nonfatal myocardial infarction (MI) as a function of heart rate
achieved at the end of the study in the beta-blocker group. The diameter of the
circles represents the weight of each individual trial. The line represents the
regression fit with 95% confidence interval for the effect sizes. VACS  Veter-
ans Administration Cooperative Study Group on Antihypertensive Agents; other
abbreviations as in Figure 2.
H
r
b
(
0
c
0
p
E
m
r
0
w
S
o
b
2
G
s
0
p
E
m
l
p
i
A
i
c
p
0
a
0
w
n
m
l
p
m
1486 Bangalore et al. JACC Vol. 52, No. 18, 2008
Beta-Blockers and Heart Rate October 28, 2008:1482–9eart failure. For the outcome of heart failure (5 RCTs
eporting this outcome), the risk reduction was comparable
etween the beta-blocker group and the comparison group
1.8% vs. 1.8%; pooled RR: 1.00; 95% CI: 0.83 to 1.22; p
.959). Given heterogeneity in the analysis (heterogeneity
hi-square 11.73 [df 5]; p 0.039; I2 57.4%; Tau2
.0295), a random effects model was used. The tests for
ublication bias were negative (Begg’s test p  0.851;
gger’s p  0.927).
The relationship between heart rate at the end of treat-
ent and risk of heart failure followed an inverse linear
Figure 5 Risk of HF as Function of Heart Rate
Relative risk of heart failure (HF) as a function of heart rate achieved at the
end of the study in the beta-blocker group. The diameter of the circles repre-
sents the weight of each individual trial. The line represents the regression fit
with 95% confidence interval for the effect sizes. Abbreviations as in Figure 2.
Figure 6 Risk of Stroke as Function of Heart Rate
Relative risk of stroke as a function of heart rate achieved at the end of the
study in the beta-blocker group. The diameter of the circles represents the
weight of each individual trial. The line represents the regression fit with 95%
confidence interval for the effect sizes. Abbreviations as in Figure 2.eelationship (y  2.8309  0.0262x; r  0.6368, p 
.00001) so that the relative risk of heart failure increased
ith decreasing heart rate at treatment end (Fig. 5).
troke. For the outcome of stroke (8 RCTs reporting this
utcome), the risk reduction was comparable between the
eta-blocker group and the comparison group (2.8% vs.
.3%; pooled RR: 1.04; 95% CI: 0.84 to 1.28; p  0.746).
iven heterogeneity in the analysis (heterogeneity chi-
quare  23.39 [df  8]; p  0.003; I2  65.8%; Tau2 
.0497), a random effects model was used. The tests for
ublication bias were negative (Begg’s test p  0.251;
gger’s p  0.063).
The relationship between heart rate at the end of treat-
ent and risk of stroke showed a trend toward an inverse
inear relationship (y  2.095  0.0141x; r  0.2011;
 0.0602) so that the relative risk of stroke trended to
ncrease with decreasing heart rate at treatment end (Fig. 6).
ll-cause mortality. For the outcome of all-cause mortal-
ty (7 RCTs reporting this outcome), the risk reduction was
omparable between the beta-blocker group and the com-
arison group (7.0% vs. 6.7%; pooled RR: 1.01; 95% CI:
.90 to 1.13; p  0.870). Given heterogeneity in the
nalysis (heterogeneity chi-square  17.01 [df  7]; p 
.017; I2 58.9%; Tau2 0.0112), a random effects model
as used. However, the tests for publication bias were
egative (Begg’s test p  0.711; Egger’s p  0.238).
The relationship between heart rate at the end of treat-
ent and risk of all-cause mortality followed an inverse
inear relationship (y  1.8336  0.0118x; r  0.5112;
 0.0000001) so that the relative risk of all-cause
ortality increased with decreasing heart rate at treatment
Figure 7 Risk of All-Cause
Mortality as Function of Heart Rate
Relative risk of all-cause mortality as a function of heart rate achieved at the
end of the study in the beta-blocker group. The diameter of the circles repre-
sents the weight of each individual trial. The line represents the regression fit
with 95% confidence interval for the effect sizes. Abbreviations as in Figure 2.nd (Fig. 7).
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his systematic review of RCTs investigated the role of
eart rate on the risk of cardiovascular events in patients
ith hypertension treated with a beta-blocker. In contrast to
atients with MI, heart failure, and known CAD, a slower
eart rate with a beta-blocker was associated with increased
isk of cardiovascular events and death among hypertensive
atients: the slower the heart rate, the greater the risk.
esting heart rate in health. In persons with no known
ardiovascular disease, a faster heart rate is associated with
n increased risk of cardiovascular events. In the Framing-
am cohort of 5,070 subjects free of cardiovascular disease at
ntry who were followed up for 30 years, for both genders,
t all ages, all-cause, cardiovascular, and coronary mortality
ates increased progressively in relation to antecedent heart
ates determined biennially (1). Similarly, in a study of
,916 men in 3 Chicago epidemiological studies, mortality
rom both cardiovascular and noncardiovascular causes gen-
rally increased with increasing heart rate (22). Other
tudies in the U.S. and United Kingdom have found an
ssociation between heart rate and cardiovascular events
mong patients without cardiovascular disease (23,24). The
ypothesis put forward to explain this association is that a
igher resting heart rate may be an indicator of increased
ympathetic activity, which has been implicated in the
evelopment of cardiovascular disease risk factors (25) such
s hypertension (26) and diabetes mellitus (27) and has been
irectly related to coronary heart disease morbidity (28) and
ortality (29), including sudden cardiac death (30) and total
ortality (31).
Conversely, physical activity and endurance training de-
reases resting heart rate and has been documented to
educe cardiovascular morbidity and mortality. The favor-
ble effect of aerobic conditioning has been attributed to a
eduction in the sympathetic activity and an increase in the
arasympathetic activity that, in addition to other myriad
ffects, also results in a decrease in heart rate. However,
here are no data showing that pharmacological reduction of
eart rate in persons free of cardiovascular disease has any
eneficial effects.
esting heart rate in cardiovascular disease. Among the
4,913 patients with suspected or proven CAD from the
ASS (Coronary Artery Surgery Study) registry followed
p for 14.7 years, all-cause and cardiovascular mortality as
ell as cardiovascular rehospitalization rates were increased
ith increasing heart rate (p 0.0001) (5). Similarly, in the
cute MI cohort (SPRINT-2 [Secondary Prevention Rein-
arction Israeli Nifedipine Trial-2] and GISSI-2 [Gruppo
taliano per lo Studio della Saprawivenza nell’Infarto
iocardico-2] studies), in-hospital mortality increased with
ncreased admission heart rate (32,33). Similar results have
een shown within the post-MI cohort as well. In patients
ith known CAD (previous MI, revascularization, or an-
ina), a higher heart rate results in higher work load on the
eart in the presence of a compromised coronary circulation. pAlthough higher heart rate was a poor prognostic indi-
ator in this cohort, pharmacological reduction of heart rate
as proven to reduce this risk. Kjekshus et al. (7) in a
eta-analysis of acute MI trials showed that a reduction in
eart rate of at least 15 beats/min during infarct evolution
as associated with a reduction of infarct size between 25%
nd 30%. In an analysis of post-MI trials, a relationship
etween actual reduction in heart rate by using a beta-
locker and reduction in mortality (r  0.60) and nonfatal
einfarctions (r  0.59) was seen (7). Kjekshus et al. (7)
ypothesized that the beneficial effect of beta-blockers was
elated to a quantitative reduction in heart rate, probably
ndicating an anti-ischemic effect. Similarly, among patients
ith stable angina as well as among post-MI patients (34),
eart rate lowering calcium-channel blockers were found to
xert beneficial effects (35). In the INITIATIVE (Interna-
ional Trial of the Antianginal Effects of Ivabradine Com-
ared to Atenolol) trial (36), ivabradine, a new I(f) inhibitor
hat acts specifically on the pacemaker activity of the
inoatrial node and hence may be considered as a pure heart
ate lowering agent, was found to be noninferior to atenolol
or patients with stable angina, emphasizing the role of
eart rate in patients with angina. Similarly, in patients with
eart failure, drugs that increase heart rate (positive inotro-
ic substances) augment mortality, whereas drugs that
ecrease heart rate (beta-blockers) reduce mortality (8).
esting heart rate in hypertension. Among 4,530 un-
reated hypertensive patients (blood pressure 140 mm Hg
ystolic or 90 mm Hg diastolic) patients in the Framing-
am study, the risk of cardiovascular events increased with
ncreased resting heart rate, with an odds ratio for each 40
eats/min increment in heart rate of 1.68 to 1.70 (95% CI:
.08 to 2.67) for cardiovascular mortality and 2.14 to 2.18
95% CI: 1.59 to 2.88) for all-cause mortality (1). Similar
esults have been shown in other studies in the hypertensive
ohort (37).
However, no study to date has shown that pharmacolog-
cal reduction of heart rate is beneficial for patients with
ypertension. To the contrary, the results of the present
nalyses show that reduction of heart rate with beta-blocker
herapy is associated with increased risk of cardiovascular
vents.
To some extent, our findings could be explained by an
ncrease in central aortic pressure and/or pulse pressure with
harmacological heart rate lowering. The central aortic
ressure depends on wave reflection from the periphery. In
atients with slower heart rate, the reflected wave reaches
he next wave in systole (instead of diastole), and hence may
ncrease central aortic pressure. Thus, pharmacologically
nduced bradycardia leads to dyssynchrony or uncoupling
etween outgoing and reflected wave, thereby elevating
entral aortic pressure. In fact, in the CAFE (Conduit
rtery Functional End Point) study (38), for the same
eripheral blood pressure, 4.3 mm Hg higher central aortic
ystolic blood pressure and 3.0 mm Hg higher central aortic
ulse pressure were noted with atenolol-based treatment
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Beta-Blockers and Heart Rate October 28, 2008:1482–9ompared with the amlodipine-based treatment, resulting in
14% higher risk of coronary events and 23% increase in
troke rate. The CAFE study suggested that the central
ortic systolic blood pressure (measured indirectly by radial
rtery applanation tonometry) may be more predictive of
ardiovascular events than the traditional peripheral (bra-
hial) blood pressure measurements. A second possible
xplanation of our findings could be related to an increase in
ulse pressure. As mean arterial pressure is a product of
ardiac output (heart rate  stroke volume) and peripheral
ascular resistance, a decrease in heart rate with a beta-
locker should result in higher stroke volume, serving to
aintain cardiac output. A higher stroke volume, in turn,
esults in increased systolic pressure and decreased diastolic
ressure, thus elevating the pulse pressure. Pulse pressure
as been identified as an independent predictor of cardio-
ascular events among patients with hypertension (39).
tudy limitations. As in other meta-analyses, given the
ack of data in the each trial, we did not adjust our analyses
or dose of medications used or for compliance with
ssigned therapy. Although we have shown an association
etween risk of cardiovascular events and heart rate, further
tudies are needed to establish causation. It should also be
oted that the beta-blocker used in the studies was mainly
tenolol, and hence, any meaningful extrapolation of these
esults to other beta-blockers, including the newer vasodi-
ating beta-blockers, should be done with caution. We have
sed relative risk (beta-blockers vs. controls) in each of the
tudies as a function of heart rate achieved. Given that all of
he trials were RCTs, the baseline characteristics between
he beta-blocker and the comparison group were well
atched. However, given lack of patient level data, we were
nable to control for between-study differences in the
aseline clinical characteristics.
onclusions
n contrast to patients with MI and heart failure, beta-
locker–associated reduction in heart rate increased the risk
f cardiovascular events and death for hypertensive patients.
harmacologically-induced bradycardia may lead to dyssyn-
hrony between outgoing and reflected pulse wave, thereby
ncreasing central aortic pressure and the hemodynamic
urden to the target organs.
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